Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04770922 · ClinicalTrials.gov registry record
Pharmacogenomic Analysis in Pediatric Acute Lymphoblastic Leukemia
A clinical trial of Acute Lymphoblastic Leukemia, Pediatric and Adverse Drug Event, sponsored by Cipherome.
- Completed
- Registry status
- 80
- Enrollment target
- 1
- Study location
NCT04770922: Completed study of Acute Lymphoblastic Leukemia, Pediatric and Adverse Drug Event, sponsored by Cipherome.
NCT04770922 is a study of Acute Lymphoblastic Leukemia, Pediatric and Adverse Drug Event that has completed, run by Cipherome. The registered enrollment target is 80 participants, below the 114-participant average among 8 other Acute Lymphoblastic Leukemia, Pediatric trials with a reported enrollment target (30% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04770922, a study of Acute Lymphoblastic Leukemia, Pediatric and Adverse Drug Event, has completed, sponsored by Cipherome.
- COMPLETED
- Registry status
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a retrospective biobank study evaluating the impact of novel genetic variants in a population of 6-mercaptopurine treated pediatric acute lymphoblastic leukemia patients.
Primary Outcome
Objective is to clinically validate the presence of novel genetic variants and its impact on adverse drug reactions in a population of pediatric ALL patients treated with 6-MP
Conditions Studied
Study Locations (1)
California
- Stanford University - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2021-02-23 |
| Est. Completion | 2021-11-10 |
What the finished NCT04770922 record still lists
NCT04770922 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 114-participant average among 8 other Acute Lymphoblastic Leukemia, Pediatric trials with a reported enrollment target (30% lower).
The record links to 2 conditions, with Acute Lymphoblastic Leukemia, Pediatric appearing as the primary indexed condition, and to 0 interventions.
NCT04770922 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04770922 about?
NCT04770922 is a clinical study titled "Pharmacogenomic Analysis in Pediatric Acute Lymphoblastic Leukemia". This is a retrospective biobank study evaluating the impact of novel genetic variants in a population of 6-mercaptopurine treated pediatric acute lymphoblastic leukemia patients.
What is the current status of trial NCT04770922?
This trial is currently completed. The enrollment target is 80 participants. The study started on 2021-02-23. Estimated completion is 2021-11-10.
What conditions does trial NCT04770922 study?
This clinical trial studies the following conditions: Acute Lymphoblastic Leukemia, Pediatric, Adverse Drug Event.
Who is sponsoring clinical trial NCT04770922?
This trial is sponsored by Cipherome, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04770922 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Lymphoblastic Leukemia, Pediatric
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04770922's enrollment target sits among peer trials
80 4th of 8 higher than 5 of 8 other Acute Lymphoblastic Leukemia, Pediatric trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Lymphoblastic Leukemia, Pediatric trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Brain MRF in Children, Adolescents and Young Adults With Acute Leukemia
RECRUITING · NA
-
Behavioral Parenting Skills as a Novel Target for Improving Pediatric Medication Adherence: Study 3
RECRUITING · NA
-
Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (RELPALL2)
RECRUITING · Phase 1
-
Massage Impact on Sleep in Pediatric Oncology
RECRUITING · NA
-
Virtual Reality During Lumbar Punctures in Acute Lymphoblastic Leukemia
RECRUITING · NA
-
CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI